StratifiDen
DENGUE FEVER
A global fast-emerging pandemic-prone viral disease
20,000
400,000,000
people have Dengue infections every year
500,000
people progressed on to develop severe Dengue and required hospitalization
hospitalized severe Dengue patients die from the disease
US$17.7 Billion
worth of socioeconomic cost
3.9 Billion
world population
at risk of Dengue
infections every year
2 Billion
more people at risk of Dengue infection by 2080
CHALLENGE
The challenge in the clinical management of Dengue is how to accurately predict which patients will develop severe Dengue in the early phase of the disease to determine whether the patient needs to be hospitalized.
.png)
Suspected Dengue case
Patient visits the hospital to seek treatment
Patient gets hospitalized if they exhibit 1 or more warning signs
Warning signs include:
-
Abdominal pain or tenderness
-
Persistent vomiting
-
Clinical fluid accumulation
-
Mucosal bleed
-
Lethargy or restlessness
-
Liver enlargment >2 cm
-
Increase in HCT concurrent with rapid decrease in platelet count
Unnecessary hospitalization as over 50% of hospitalized Dengue patients do not develop severe Dengue
Increase in unnecessary healthcare expenses and burden to healthcare system
INTRODUCING
STRATIFIDEN
StraifiDen is the world's first predictive test for severe dengue, revolutionizing dengue management with its ability to quickly assess a patient's risk of developing severe symptoms.
This patented, breakthrough test measures specific biomarkers to predict the severity of dengue, guiding crucial decisions about hospitalization.
Suspected Dengue case
Patient visits the hospital to seek treatment
Use of StratifiDen™ test to predict risk of severe Dengue
Patient gets hospitalized if predicted to develop severe Dengue
More focused medical attention and aggressive supportive treatment on patients with severe Dengue
Patient gets triaged to outpatient care if predicted not to develop severe Dengue
Avoid unnecessary hospitalization
Reduced unnecessary healthcare expenses
HOW IT WORKS
StraifiDen measures specific biomarkers associated with severe dengue, providing an early warning system.
If a patient is predicted to develop severe dengue, they will be promptly hospitalized, ensuring focused inpatient care.
Conversely, those not at risk are directed to outpatient care, streamlining the standard of care and ensuring each patient receives the appropriate level of attention.
1
2
3
4
Collect patient's blood sample
Perform assay using StratifiDen™ to detect presence of biomarkers
Quantify analytes by colour intensity
Determine if patient will go on to develop severe Dengue
BENEFITS
Reduction of hospitalization burden
StratifiDen™ can reduce hospitalization burden by up to 67%, which helps to prevent overwhelming of the healthcare system.
Efficiency & Cost Savings
Directs low- risk patients to outpatient care, optimising healthcare resources and patient outcomes
Ease of anxiety
Patients and their family members can be informed in advance of disease outcome.
.png)
Targeted Care
Ensure patients at risk of severe dengue receive immediate and focused inpatient care
Early Detection
Provides early insights into the risk of severe dengue, enabling timely intervention
Assay Accuracy
90% sensitivity and 97% specificity.*
* Based on pre-clinical studies.
